Skip to main content

Health condition

Carotid body tumour, paragangliomas, genetics and modern treatment.

A rare vascular tumour at the carotid bifurcation, part of a wider paraganglioma family. Diagnosis, SDHx genetics and specialist care all matter.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Editorial team

    Written by our editorial team from the UK sources listed on each page.

  • 02

    Sourced from guidance

    Checked against ENT UK, BAHNO, ESMO and NHS specialist head and neck standards.

  • 03

    Current for 2026

    Reflects modern practice including 68Ga-DOTATATE PET-CT, SDHx genetic panels and PRRT for metastatic paraganglioma.

Key facts

Carotid body tumour at a glance.

The essentials, in plain English - what it is, how often it runs in families, and how it is treated in the UK.

  • What it is

    A rare, usually benign tumour of chemoreceptor tissue at the carotid bifurcation, part of the paraganglioma family.

  • Sporadic vs familial

    About 70 per cent are sporadic and 30 per cent familial, driven by SDHx, VHL, NF1, MEN2, MAX or TMEM127 mutations.

  • Related tumours

    Head and neck paragangliomas include carotid body, jugular, vagal and laryngeal sites, plus phaeochromocytoma of the adrenal gland.

  • How it presents

    A painless, slow-growing, pulsatile mass at the angle of the jaw, mobile side to side but not up and down (Fontaine sign).

  • Functioning form

    A small minority secrete catecholamines and cause hypertension, palpitations, sweating and flushing.

  • Malignant potential

    Around 5 to 10 per cent behave malignantly overall, rising to 30 to 40 per cent with SDHB mutations.

Why this guide matters

A rare tumour with high stakes.

Because it is uncommon, patients often meet clinicians who see very few cases. The three points below explain why specialist care is essential.

  • Genetics changes the plan

    Up to 30 per cent of paragangliomas are hereditary, and SDHx status changes both surveillance and metastatic risk.

  • Imaging avoids biopsy

    Duplex, MRI, CT angiography and 68Ga-DOTATATE PET-CT together make a confident diagnosis without a dangerous needle biopsy.

  • Treatment is a real choice

    Surgery, external radiotherapy, stereotactic radiosurgery and PRRT each have a role - the right answer depends on you.

How the diagnosis is made

From neck lump to a specialist plan.

The steps a UK head and neck team will normally follow, in order - so you know what to expect and why.

  1. 01

    Assessing

    History and neck exam

    A careful look at the pulsatile lateral neck mass, cranial nerves and blood pressure, plus family history of paragangliomas.

  2. 02

    Assessing

    Duplex ultrasound

    First-line imaging shows a highly vascular mass splaying the internal and external carotid arteries.

  3. 03

    Assessing

    Biochemistry to exclude functioning tumour

    Plasma metanephrines and normetanephrines, plus 24 hour urinary catecholamines, before any intervention.

  4. 04

    Confirming

    MRI and MR angiography of the neck

    A T2 hyperintense lesion with the classic salt and pepper appearance from flow voids in a vascular tumour.

  5. 05

    Confirming

    CT angiography and skull base CT

    Defines bony involvement, feeding vessels and surgical planning, especially for jugular and vagal sites.

  6. 06

    Confirming

    68Ga-DOTATATE PET-CT

    Increasingly the gold standard for detecting somatostatin receptor expressing paragangliomas, multifocal disease and metastases.

  7. 07

    Preparing

    Genetic testing and cascade screening

    A germline panel for SDHx, VHL, NF1, MEN2, MAX, TMEM127 and FH, with family testing and annual surveillance imaging.

Typical timeline: from first neck lump to an MDT plan in a few weeks in a specialist centre.

Symptoms

What a carotid body tumour actually feels like.

Most patients notice a slow-growing lump. A minority present with cranial nerve symptoms or catecholamine excess.

  • Painless pulsatile neck mass

    A slow-growing lump at the angle of the jaw or upper lateral neck, often noticed while shaving or applying make-up.

  • Fontaine sign

    The mass is mobile from side to side over the carotid bifurcation but not up and down, a classic clinical clue.

  • Audible bruit

    A soft bruit may be heard on auscultation over the mass, reflecting its rich blood supply.

  • Cranial nerve symptoms

    Larger tumours may compress nerves IX, X, XI and XII, causing hoarseness, tongue weakness or shoulder droop.

  • Carotid sinus syndrome and syncope

    Some patients report dizziness, syncope or bradycardia from carotid sinus stimulation by the tumour.

  • Catecholamine excess

    Rarely, a functioning paraganglioma causes episodic hypertension, palpitations, headache, sweating and flushing.

  • Bilateral or multifocal disease

    Bilateral carotid body tumours or multiple paragangliomas raise the likelihood of an inherited SDHx syndrome.

  • Red flag - rapid growth or nodes

    Rapid growth, cervical lymphadenopathy or distant symptoms may indicate malignant behaviour, more common with SDHB.

Treatment

How carotid body tumours are treated in the UK.

  • Specialist head and neck MDT

    Every case is discussed by a skull base, vascular, endocrine, oncology and genetics team before a plan is set.

  • Surgical resection

    The mainstay for accessible, younger and functioning tumours - Shamblin I and II usually straightforward, III often needs carotid reconstruction.

  • Preoperative embolisation

    Performed 24 to 48 hours before surgery for Shamblin II and III tumours to reduce intraoperative blood loss.

  • External beam radiotherapy

    A well-tolerated option for older or high risk patients, with excellent long-term local control of the tumour.

  • Stereotactic radiosurgery

    Gamma Knife or CyberKnife for inoperable, bilateral or multi-site paragangliomas, with local control around 90 per cent.

  • Active surveillance

    Small, asymptomatic, slow-growing tumours in older patients may be safely monitored with serial imaging.

  • Preoperative alpha blockade

    Functioning tumours are prepared with phenoxybenzamine or doxazosin, mirroring phaeochromocytoma protocols.

  • PRRT and systemic therapy

    Metastatic paragangliomas may be treated with 177Lu-DOTATATE, sunitinib or temozolomide in a specialist NET service.

Shamblin classification

Surgical risk is graded by the Shamblin system: I small tumours easily separated from vessels; II larger tumours adherent to the carotid arteries and partially encasing them; III tumours completely encasing the vessels, often requiring vascular reconstruction or grafting and carrying the highest risk of cranial nerve injury.

What this guide is based on

The sources behind every claim on this page.

UK national guidance and international specialist society standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your head and neck surgeon, endocrinologist or clinical geneticist knows your case and can tell you which parts apply to you.

  • ENT UK and BAHNO. Head and neck paraganglioma guidance.

  • ESMO Clinical Practice Guidelines. Neuroendocrine and paraganglioma tumours.

  • European Society of Endocrinology. Clinical practice guideline on phaeochromocytoma and paraganglioma.

  • NHS England service specification for complex head and neck cancer and skull base surgery.

Red flags

When a neck lump needs urgent specialist attention.

Some features change the pace and the plan. These are the ones that shouldn’t wait.

  • Suspected functioning tumour

    Episodic hypertension, palpitations, sweating or headache means biochemistry and alpha blockade before any procedure.

  • Bilateral neck masses

    Bilateral pulsatile masses strongly suggest inherited paraganglioma syndrome and need urgent specialist review.

  • Rapid growth or lymphadenopathy

    Fast growth, hard nodes or cranial neuropathy raise concern for malignant paraganglioma, especially with SDHB mutation.

  • Never biopsy blindly

    Percutaneous biopsy is avoided due to serious risk of bleeding, hypertensive crisis and vasospasm.

  • Family history of PGL or phaeo

    Any first degree relative with paraganglioma, phaeochromocytoma or head and neck tumours warrants genetic referral.

  • Pregnancy with a known lesion

    Functioning tumours in pregnancy carry high maternal and fetal risk and need combined obstetric and endocrine care.

  • New cranial nerve deficit

    Hoarseness, tongue weakness, dysphagia or shoulder drop needs urgent imaging and MDT discussion.

  • Syncope with neck pressure

    Fainting triggered by turning the head or wearing a tight collar suggests carotid sinus involvement.

  • Metastatic symptoms

    Bone pain, weight loss or organ specific symptoms should trigger staging with DOTATATE PET-CT.

Living with it

A rare tumour, with a lifelong plan.

Four things that make the biggest difference over the years - the right team, genetic clarity, steady surveillance and considered treatment choices.

A quiet reminder

Small tumours are much easier to treat.

Regular scans, sensible follow-up and cascade family testing turn a rare diagnosis into a manageable long-term picture.

  1. 01 Team

    Stay under a specialist MDT

    Care belongs in a UK head and neck, skull base and endocrine centre with genetics and interventional radiology on hand.

  2. 02 Genetics

    Take genetic testing seriously

    A germline panel guides your own surveillance and lets relatives be screened early, when tumours are smallest.

  3. 03 Surveillance

    Commit to lifelong follow-up

    Annual head, neck and abdominal imaging plus biochemistry catches new tumours before they cause harm.

  4. 04 Choices

    Weigh surgery against radiotherapy

    For many patients, radiotherapy or radiosurgery offers similar long-term control with fewer cranial nerve risks.

Frequently asked

Everything we get asked about carotid body tumours.

Quick answers on genetics, biopsy, imaging, surgery, radiotherapy and metastatic disease.

  • What is a carotid body tumour?

    A carotid body tumour, or carotid body paraganglioma, is a rare, usually benign tumour of chemoreceptor tissue at the carotid bifurcation in the neck. It is part of the wider family of head and neck paragangliomas and belongs to the paraganglioma and phaeochromocytoma group.

  • Is it cancer?

    Most carotid body tumours are benign, but around 5 to 10 per cent behave in a malignant way, with local invasion or distant spread. The risk is higher, around 30 to 40 per cent, in people carrying SDHB mutations. That is why genetic testing and specialist follow-up matter.

  • Do I need genetic testing?

    Yes. UK and international guidelines recommend germline testing for SDHx, VHL, NF1, MEN2, MAX, TMEM127 and FH in anyone with a paraganglioma or phaeochromocytoma. A positive result changes your own surveillance and allows family members to be screened.

  • Why is a biopsy avoided?

    Carotid body tumours are extremely vascular and may be catecholamine-secreting. A needle biopsy risks serious bleeding, vessel injury and a hypertensive crisis. Diagnosis is made with imaging and biochemistry instead.

  • Is surgery or radiotherapy better?

    Both work well. Surgery is preferred for younger patients, functioning tumours and Shamblin I or II lesions, often with preoperative embolisation. Radiotherapy or stereotactic radiosurgery is chosen for inoperable, bilateral, elderly or high risk cases, with local control around 90 per cent.

  • What happens if the tumour spreads?

    Metastatic paragangliomas are managed by a specialist neuroendocrine tumour service. Options include peptide receptor radionuclide therapy with 177Lu-DOTATATE, tyrosine kinase inhibitors such as sunitinib, chemotherapy with temozolomide and clinical trials.

Related content

Keep reading.